Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.
2.

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.

Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbøl TB.

J Pharmacol Exp Ther. 2012 Mar;340(3):666-75. doi: 10.1124/jpet.111.189068. Epub 2011 Dec 9.

3.

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.

Alvarez E, Perez V, Dragheim M, Loft H, Artigas F.

Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600. doi: 10.1017/S1461145711001027. Epub 2011 Jul 18.

4.

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.

Mahableshwarkar AR, Jacobsen PL, Chen Y.

Curr Med Res Opin. 2013 Mar;29(3):217-26. doi: 10.1185/03007995.2012.761600. Epub 2013 Jan 17.

PMID:
23252878
5.

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.

Baldwin DS, Hansen T, Florea I.

Curr Med Res Opin. 2012 Oct;28(10):1717-24. doi: 10.1185/03007995.2012.725035. Epub 2012 Sep 17.

PMID:
22978748
6.

Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.

Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C.

Eur Neuropsychopharmacol. 2013 Feb;23(2):133-45. doi: 10.1016/j.euroneuro.2012.04.006. Epub 2012 May 20.

PMID:
22612991
7.

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM.

Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. doi: 10.1017/S1461145710000659. Epub 2010 Jun 23.

PMID:
20569520
8.

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.

J Clin Psychiatry. 2012 Jul;73(7):953-9. doi: 10.4088/JCP.11m07470.

PMID:
22901346
9.

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).

Baldwin DS, Loft H, Dragheim M.

Eur Neuropsychopharmacol. 2012 Jul;22(7):482-91. doi: 10.1016/j.euroneuro.2011.11.008. Epub 2011 Dec 30.

PMID:
22209361
10.

Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.

Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.

Eur Neuropsychopharmacol. 2012 Dec;22(12):847-57. doi: 10.1016/j.euroneuro.2012.07.012. Epub 2012 Aug 14.

PMID:
22898365
11.
12.

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP.

J Clin Oncol. 2008 May 1;26(13):2124-30. doi: 10.1200/JCO.2007.15.2553.

PMID:
18445841
13.

Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.

Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A, Bombardieri E.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):84-91.

14.

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.

Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.

Eur Neuropsychopharmacol. 2012 Dec;22(12):858-66. doi: 10.1016/j.euroneuro.2012.07.011. Epub 2012 Aug 15.

PMID:
22901736
15.

Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, Ng QK, Mäcke HR, Müller-Brand J, Rochlitz C, Briel M, Walter MA.

J Clin Oncol. 2012 Apr 1;30(10):1100-6. doi: 10.1200/JCO.2011.37.2151. Epub 2012 Mar 5.

PMID:
22393097
16.

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C.

Pharmacol Biochem Behav. 2013 Apr;105:41-50. doi: 10.1016/j.pbb.2013.01.019. Epub 2013 Feb 1.

17.

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.

Boulenger JP, Loft H, Florea I.

J Psychopharmacol. 2012 Nov;26(11):1408-16. doi: 10.1177/0269881112441866. Epub 2012 Apr 9.

PMID:
22495621
18.

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB.

J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12.

PMID:
21486038
19.

JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.

De Grandis M, Cambot M, Wautier MP, Cassinat B, Chomienne C, Colin Y, Wautier JL, Le Van Kim C, El Nemer W.

Blood. 2013 Jan 24;121(4):658-65. doi: 10.1182/blood-2012-07-440487. Epub 2012 Nov 16.

20.

Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu₄ receptor.

Sławińska A, Wierońska JM, Stachowicz K, Pałucha-Poniewiera A, Uberti MA, Bacolod MA, Doller D, Pilc A.

Neuropharmacology. 2013 Mar;66:225-35. doi: 10.1016/j.neuropharm.2012.05.001. Epub 2012 May 23.

PMID:
22634361

Supplemental Content

Support Center